Here’s a question that trips up a lot of program teams: if a compound isn’t intended for the eye, why would you need a veterinary ophthalmologist involved in its toxicology program at all? The answer is that ocular findings have a way of showing up uninvited, and when they do, the quality of the eye exam behind that finding can determine whether a program moves forward or stalls.
This dynamic surprises programs less experienced with ophthalmology more than almost anything else in nonclinical planning, in part because the eye is so frequently treated as a specialty organ system relevant only to ophthalmic indications. In reality, the eye sits downstream of systemic circulation and is often exposed to a compound at concentrations that reflect underlying pharmacology or off-target activity long before a clinical sign becomes obvious anywhere else in the body, which is exactly why unplanned ocular findings tend to surface in general toxicology studies more often than sponsors expect.
What a Veterinary Ophthalmologist Brings to Ocular Drug Programs
For ophthalmic therapeutics specifically, a board-certified veterinary ophthalmologist brings expertise that general toxicologic pathologists and laboratory veterinarians typically don’t have: advanced slit-lamp biomicroscopy, indirect ophthalmoscopy, retinal imaging interpretation, and deep familiarity with ocular pharmacology and disease mechanisms in animals. Perhaps most valuable is the ability to tell a subtle compound or device-related finding apart from an incidental, background or other incidental lesion (i.e. not compound or device related), then correlate that clinical observation with the histopathology. The trained veterinary ophthalmologist can identify subtle inflammatory changes of the vascular coat of the eye including visualizing individual cells in the anterior chamber and vitreous and direct visualization of the neural coat (retina) and its vascular supply can disclose early “off target” adverse events that can dramatically affect development programs.
In practice, that expertise tends to show up as earlier detection of ocular toxicity, more accurate determination of the no-observed-adverse-effect level (NOAEL), cleaner separation of incidental findings from genuine drug/device effects, and stronger credibility during FDA interactions. For intravitreal, topical, gene therapy, and sustained-release ocular products, specialist involvement is generally considered best practice rather than a nice-to-have.
The Case for General Toxicology Programs
Even when a drug was never meant to touch the eye, ocular findings can become the dose-limiting toxicity that shapes the entire program. Phospholipidosis-associated corneal changes, lens opacities, retinal degeneration, optic nerve toxicity, uveal inflammation, corneal epithelial changes (e.g. antibody-drug conjugate [ADC] off target effects) vascular changes, and drug-induced dry eye are all findings that can turn up in general toxicology studies. Many are subtle enough to be missed, or misclassified, without specialized ophthalmic expertise on hand to interpret them.
How Regulators View It
FDA and ICH guidance don’t universally mandate a veterinary ophthalmologist’s involvement, but reviewers frequently place real weight on ophthalmic evaluations performed by specialists. This is particularly true when ocular findings are observed, when the mechanism of action suggests ocular risk, when the drug’s target is expressed in ocular tissue, when biologics or gene therapies are involved, or when the study runs long enough to be considered chronic. When ocular findings become a major discussion point during regulatory review, having those examinations conducted and interpreted by a board-certified specialist can substantially strengthen the nonclinical package.
Value That Extends Beyond the Exam Room
Experienced veterinary ophthalmologists tend to contribute well beyond the slit lamp and ophthalmoscope. Their work often includes helping choose species for ocular endpoints, developing ophthalmic examination protocols, interpreting electroretinography (ERG) and OCT imaging, correlating findings with histopathology, assessing whether a lesion is reversible or truly adverse, and helping prepare responses to regulatory questions.
The Economics of Getting This Right
The cost of bringing in a veterinary ophthalmologist is usually small relative to the overall cost of a GLP toxicology study. Missing or misinterpreting an ocular signal, on the other hand, can lead to additional studies, delayed IND submissions, unexpected regulatory questions, incorrect dose selection, an asset being placed on clinical hold, or in the worst case, program termination. These risks are severe enough that the ROI on veterinary ophthalmology support is almost always favorable.
What Experienced Teams Actually Do
Among experienced ophthalmic drug developers, the standard expectation breaks down fairly cleanly. Ocular drug programs involve a board-certified veterinary ophthalmologist routinely, throughout development. General toxicology programs bring one in whenever there’s a plausible ocular liability: an unexplained ophthalmic finding, a CNS target, a gene therapy or biologic candidate, any asset that could affect epithelial kinetics, a chronic dosing study, or any hint of retinal, lenticular, corneal, or optic nerve effects.
Put simply: a veterinary ophthalmologist isn’t merely someone who examines eyes. They’re a translational safety expert who helps determine whether an ocular finding represents background biology, a manageable pharmacologic effect, or a program-threatening toxicology signal.